App for through

PTO/SB/08A (10-96) for through 10/31/99. OMB 0651-0031 Office: U.S. DEPARTMENT OF COMMERCE

Patent and Tradema... Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons at a required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

C Substitute for form 1449/01

CA TRADE

STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 1

Complete if Known				
Application Number	09/771,151			
Filing Date	01/26/2001			
First Named Inventor	Danilo D. Lasic			
Group Art Unit	1615			
Examiner Name	Unknown			
Attorney Docket Number	5325-0169.30			

				U.S. PATENT DOC	UMENTS	
Examine Initials	Cite No.1	U.S. Patent I	Ocument Kind Code ² (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
TAL	1A_	5,013,556		Liposome Technology, Inc.	05/07/1991	
	2A	5,631,018		Seguus Pharma. Inc.	05/20/1997	
1/	3A	5,891,468		Sequus Pharma. Inc.	04/06/1999	
	4A	5,945,122		Sequus Pharma. Inc.	08/31/1999	
7						
	ļ					
						·

				FOR	EIGN PATENT DOCUMENT	rs		
Examiner Initials	Cite No.1	Office	Foreign Patent Do	Cument Kind Code ^s (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T6
7 .	1B	wo	98/07409		Seguus Pharma. Inc	02/26/1998		
	2B	EP	0 551 169		Takeda Chem. Ind.	07/14/1993		
								-
								-
								-
		 				<u> </u>		-

				1	
Examiner Signature	Wh	Date Considered	ئ.	102	

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08B (10-96)
Appl of through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

ORMATION DISCLOSURE MENT BY APPLICANT

(use as many sheets as necessary)

Sheet of |2

Co	Complete if Known	
Application Number	09/771,151	<u> </u>
Filing Date	01/26/2001	4
First Named Inventor	Danilo D. Lasic	FR
Group Art Unit	1615	16
Examiner Name	Unknown	Ö
Attorney Docket Number	5325-0169.30	1600/290
		$\overline{\approx}$

		OTHER PRIOR ART NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
W	1 <u>C</u>	A. GABIZON ET AL., "Liposomes as in Vivo Carriers of Adriamycin: Reduced," Cancer Research, p. 4734-4739, (November 17, 1982).	
	2C	FREISE, J. ET AL., "Pharmacokinetics of Liposome Encapsulated," Arch. Int. Pharmacodyn, p. 180-192, (June 19, 1982).	
	3C	GONDAL, J.A., ET AL., "Comparative Pharmacological, Toxicological," Eur. J. Cancer, Vol. 29A (No. 11), p. 1536-1542, (June 19, 1993).	
	4C	SUR, B., ET AL., "Effect of Liposomal Encapsulation of cis-Platinum," Oncology, p. 372-376, (June 19, 1983).	
	5C	WEISS, R. B. ET AL., "New Cisplatin Analogues in Development," Drugs, Adis International Ltd., Vol. 46 (No. 3), p. 360-377, (June 19, 1993).	
	6C	FENSKE, P.B., "Structural and Motional Properties of Vesicles," Chem. Phys. Lipids, Elsevier Scientific Publishers Ireland Ltd., p. 143-162, (June 19, 1993).	
	7C	TILCOCK, C.P.S., "Lipid Polymorphism," Chem. Phys. Lipids, Elsevier Scientific Publishers Ireland Ltd., p. 109-125, (June 19, 1986).	
	8C	BERNERS-PRICE, S. J. ET AL., "Stereospecific Hydrogen-Bonding in," J. Am. Chem.Soc., p. 8649-8659, (June 19, 1993).	
		APPLETON, T.G., ET AL., "N and Pt NMR Spectra of Platinum," Inorg. Chem., p. 4685-4693, (June 19, 1985).	
	10C	C. J. BOREHAM, ET AL., "A Pt and N N.M.R. Study of the Anticancer," Aust. J. Chem., p. 659-664, (June 19, 1981).	
	11C	LICHTENBERG, D. ET AL., "Liposomes: Preparation, Characterization," Methods of Biochem. Analysis, Wiley (New York), p. 337-463, (June 19, 1998).	

Examiner Signature	Kren	Date Considered	102

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

JUL 2 3 2001

Sheet

			Appr	or through	10/31/99. OMB	0051-0031
			Patent and Trademark	ffice: U.S. DEP/	ARTMENT OF C	OMMERCE
+ Anda	the Panaruark Poduction Act of 1995	no persons are required to respond to a co	ollection of information unle	ace it contains s	walid OMB cont	humber
Cilde	the Paperwork Reduction Act of 1993	no persons are required to respond to a cr	onection of information unit	ess il comanis a	Valid Olvid Cont	Of Hullines

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

of |2

Co	mplete if Known	主。
Application Number	09/771,151	E C
Filing Date	01/26/2001	
First Named Inventor	Danilo D. Lasic	ER ER
Group Art Unit	1615	1 6 2
Examiner Name	Unknown	90
Attorney Docket Number	5325-0169.30	1 //29

7		ō	
		OTHER PRIOR ART NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Т
W	12C	REHR, J.J. ET AL., "High-Order Multiple-Scattering," Phys. Rev. Lett., The American Physical Society, Vol. 69 (No. 23), p. 3397-3400, (June 19, 1992).	
	13C	MILBURN, G.H.W., ET AL., "The Crystal Structures of cis-and trans," Inorg. Phys. Theor., p. 1609-1616, (June 19, 1966).	
	14C	STERN, E.A., ET AL., "The UWXAFS analysis package:," Physica B, Elsevier Science B.V., p. 117-120, (June 19, 1995).	
	15C	ROY, M., ET AL., "The Amplitude Reduction Factor," J. Phys. IV France, p. 151-152, (June 19, 1997).	
	16C	MOELLER, M. ET AL., "Mineralization of Nanoparticles," Curr. Op. Coo. Interf. Sci., p. 177-187, (June 19, 1997).	
	17C	KURODA, R., ET AL., "Crystal and Molecular Structure," Inorganic Chem., p. 3620-3624, (June 19, 1983).	
	18C	FAGGIANI, R. ET AL., "Crystalline Structure and Vibrational," Canadian J. of Chem., p. 529-534, (June 19, 1982).	
	19C	SPEELMANS, G. ET AL., "The Interaction of the Anti-Cancer," Biochim. Biophys. Acta, Elsevier Science B.V., p. 60-66, (June 19, 1996).	
		HOLLY, R. ET AL., "Proton Rotating Frame Spin-Lattice," J. Chem. Phys., Vol. 108 (No. 10), p. 4183-4188, (March 8, 1998).	
	21C	BARNHAM, K.J. ET AL., "NMR Spectroscopy of Platinum," Platinum and Other Metal, Plenum Press, New York, p. 1-16, (July 17, 1996).	
Ŭ			

Examiner Signature	ulu	Date Considered	31	02
-----------------------	-----	--------------------	----	----

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.